Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate
- PMID: 21752599
- DOI: 10.1016/j.jaut.2011.06.003
Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate
Abstract
The respective roles of inflammatory and neurodegenerative processes in the pathology of multiple sclerosis (MS) and in its animal model experimental autoimmune encephalomyelitis (EAE) are controversial. Novel treatment strategies aim to operate within the CNS to induce neuroprotection and repair processes in addition to their anti-inflammatory properties. In this study we analyzed and compared the in situ pathological manifestations of EAE utilizing two different models, namely the relapsing-remitting PLP-induced and the chronic MOG-induced diseases. To characterize pathological changes, both transmission electron microscopy (TEM) and immunohistochemistry were employed. The effect of the approved MS drug glatiramer acetate (GA, Copaxone) on myelin damage/repair and on motor neuron loss/preservation was studied in both EAE models. Ultrastructural spinal cord analysis revealed multiple white matter damage foci, with different patterns in the two EAE models. Thus, the relapsing-remitting model was characterized mainly by widespread myelin damage and by remyelinating fibers, whereas in the chronic model axonal degeneration was more prevalent. Loss of lower motor neurons was manifested only in mice with chronic MOG-induced disease. In the GA-treated mice, smaller lesions, increased axonal density and higher prevalence of normal appearing axons were observed, as well as decreased demyelination and degeneration. Furthermore, quantitative analysis of the relative remyelination versus demyelination, provides for the first time evidence of significant augmentation of remyelination after GA treatment. The loss of motor neurons in GA-treated mice was also reduced in comparison to that of EAE untreated mice. These effects were obtained even when GA treatment was applied in a therapeutic schedule, namely after the appearance of clinical symptoms. Hence, the remyelination and neuronal preservation induced by GA are in support of the neuroprotective consequences of this treatment.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE.J Neuroimmunol. 2010 Aug 25;225(1-2):100-11. doi: 10.1016/j.jneuroim.2010.04.022. J Neuroimmunol. 2010. PMID: 20554028
-
Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate.Exp Neurol. 2013 Feb;240:130-44. doi: 10.1016/j.expneurol.2012.11.004. Epub 2012 Nov 12. Exp Neurol. 2013. PMID: 23153580
-
Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat.Exp Neurol. 2006 Feb;197(2):373-85. doi: 10.1016/j.expneurol.2005.10.033. Epub 2005 Dec 9. Exp Neurol. 2006. PMID: 16337942
-
Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. J Autoimmun. 2014. PMID: 24934599 Review.
-
Neuronal injury in chronic CNS inflammation.Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29. Best Pract Res Clin Anaesthesiol. 2010. PMID: 21619866 Review.
Cited by
-
Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.J Neuroimmune Pharmacol. 2013 Jun;8(3):651-63. doi: 10.1007/s11481-013-9436-x. Epub 2013 Jan 31. J Neuroimmune Pharmacol. 2013. PMID: 23370991
-
Neuron-Oligodendrocyte Interactions in the Structure and Integrity of Axons.Front Cell Dev Biol. 2021 Mar 8;9:653101. doi: 10.3389/fcell.2021.653101. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33763430 Free PMC article. Review.
-
Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation.Front Immunol. 2017 Nov 23;8:1432. doi: 10.3389/fimmu.2017.01432. eCollection 2017. Front Immunol. 2017. PMID: 29218043 Free PMC article.
-
TnP Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model.Front Immunol. 2022 Mar 24;13:857692. doi: 10.3389/fimmu.2022.857692. eCollection 2022. Front Immunol. 2022. PMID: 35401524 Free PMC article.
-
N-Phenylquinazolin-2-amine Yhhu4952 as a novel promotor for oligodendrocyte differentiation and myelination.Sci Rep. 2018 Sep 19;8(1):14040. doi: 10.1038/s41598-018-32326-0. Sci Rep. 2018. PMID: 30232349 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials